Functional diversity on synaptic plasticity mediated by endocannabinoids

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 367, Issue 1607, 2012, Pages 3242-3253

  Cachope, Roger ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

2 arachidonoyglycerol; Anandamide; Cannabinoid receptor 1; Endocannabinoids; Synaptic plasticity; Transient receptor potential 1

Indexed keywords

EID: 84868108293     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2011.0386     Document Type: Review

References (111)

1. Llano, I., Leresche, N. & Marty, A. 1991 Calcium entry increases the sensitivity of cerebellar Purkinje cells to applied GABA and decreases inhibitory synaptic currents. Neuron 6, 565-574. (doi:10.1016/0896-6273(91)90059-9)
2. Pitler, T. A. & Alger, B. E. 1992 Postsynaptic spike firing reduces synaptic GABAA responses in hippocampal pyramidal cells. J. Neurosci. 12, 4122-4132.
3. Pitler, T. A. & Alger, B. E. 1994 Depolarizationinduced suppression of GABAergic inhibition in rat hippocampal pyramidal cells: G protein involvement in a presynaptic mechanism. Neuron 13, 1447-1455. (doi:10.1016/0896-6273(94)90430-8)
4. Elphick, M. R. & Egertová, M. 2001 The neurobiology and evolution of cannabinoid signalling. Phil. Trans. R. Soc. Lond. B 356, 381-408. (doi:10.1098/rstb.2000.0787)
5. Wilson, R. I. & Nicoll, R. A. 2001 Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410, 588-592. (doi:10.1038/35069076)
6. Ohno-Shosaku, T., Maejima, T. & Kano, M. 2001 Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29, 729-738. (doi:10.1016/S0896-6273(01)00247-1)
7. Kreitzer, A. C. & Regehr, W. G. 2001 Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29, 717-727. (doi:10.1016/S0896-6273(01)00246-X)
8. Maejima, T., Hashimoto, K., Yoshida, T., Aiba, A. & Kano, M. 2001 Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 31, 463-475. (doi:10.1016/S0896-6273(01)00375-0)
9. Varma, N., Carlson, G. C., Ledent, C. & Alger, B. E. 2001 Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J. Neurosci. 21, RC188.
10. Kim, J., Isokawa, M., Ledent, C. & Alger, B. E. 2002 Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J. Neurosci. 22, 10182-10191.
11. Fukudome, Y. et al. 2004 Two distinct classes of muscarinic action on hippocampal inhibitory synapses: M2-mediated direct suppression and M1/M3-mediated indirect suppression through endocannabinoid signalling. Eur. J. Neurosci. 19, 2682-2692. (doi:10.1111/j.0953-816X.2004.03384.x)
12. Straiker, A. & Mackie, K. 2007 Metabotropic suppression of excitation in murine autaptic hippocampal neurons. J. Physiol. 578, 773-785. (doi:10.1113/jphysiol.2006.117499)
13. Best, A. R. & Regehr, W. G. 2008 Serotonin evokes endocannabinoid release and retrogradely suppresses excitatory synapses. J. Neurosci. 28, 6508-6515. (doi:10.1523/JNEUROSCI.0678-08.2008)
14. Haj-Dahmane, S. & Shen, R.-Y. 2005 The wakepromoting peptide orexin-B inhibits glutamatergic transmission to dorsal raphe nucleus serotonin neurons through retrograde endocannabinoid signaling. J. Neurosci. 25, 896-905. (doi:10.1523/JNEUROSCI.3258-04.2005)
15. Brown, S. P., Brenowitz, S. D. & Regehr, W. G. 2003 Brief presynaptic bursts evoke synapse-specific retrograde inhibition mediated by endogenous cannabinoids. Nat. Neurosci. 6, 1048-1057. (doi:10.1038/nn1126)
16. Ohno-Shosaku, T., Hashimotodani, Y., Ano, M., Takeda, S., Tsubokawa, H. & Kano, M. 2007 Endocannabinoid signalling triggered by NMDA receptor-mediated calcium entry into rat hippocampal neurons. J. Physiol. 584, 407-418. (doi:10.1113/jphysiol.2007.137505)
17. Vincent, P., Armstrong, C. M. & Marty, A. 1992 Inhibitory synaptic currents in rat cerebellar Purkinje cells: modulation by postsynaptic depolarization. J. Physiol. 456, 453-471.
18. Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S. & Howlett, A. C. 1988 Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34, 605-613.
19. Matsuda, L., Lolait, S., Brownstein, M., Young, A. C. & Bonner, T. I. 1990 Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564. (doi:10.1038/346561a0)
20. Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R. & Rice, K. C. 1990 Cannabinoid receptor localization in brain. Proc. Natl Acad. Sci. USA 87, 1932-1936. (doi:10.1073/pnas.87.5.1932)
21. Katona, I., Sperlágh, B., Sík, A., Käfalvi, A., Vizi, E. S., Mackie, K. & Freund, T. F. 1999 Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci. 19, 4544-4558.
22. Devane, W. A. et al. 1992 Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949. (doi:10.1126/science.1470919)
23. Mechoulam, R. et al. 1995 Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90. (doi:10.1016/0006-2952(95)00109-D)
24. Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A. & Waku, K. 1995 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89-97. (doi:10.1006/bbrc.1995.2437)
25. Domenici, M. R., Azad, S. C., Marsicano, G., Schierloh, A., Wotjak, C. T., Dodt, H. U., Zieglgänsberger, W., Lutz, B. & Rammes, G. 2006 Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. J. Neurosci. 26, 5794-5799. (doi:10.1523/JNEUROSCI.0372-06.2006)
26. Mátyás, F., Yanovsky, Y., Mackie, K., Kelsch, W., Misgeld, U. & Freund, T. F. 2006 Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience 137, 337-361. (doi:10.1016/j.neuroscience.2005.09.005)
27. 2+ currents by endocannabinoids released via postsynaptic mGluR activation at a calyx synapse. J. Neurosci. 24, 5955-5965. (doi:10.1523/JNEUROSCI.0768-04.2004)
28. Oropeza, V. C., Mackie, K. & Van Bockstaele, E. J. 2007 Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex. Brain Res. 1127, 36-44. (doi:10.1016/j.brainres.2006.09.110)
29. Oropeza, V. C., Page, M. E. & Van Bockstaele, E. J. 2005 Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex. Brain Res. 1046, 45-54. (doi:10.1016/j.brainres.2005.03.036)
30. Reyes, B. A. S., Rosario, J. C., Piana, P. M. T. & van Bockstaele, E. J. 2009 Cannabinoid modulation of cortical adrenergic receptors and transporters. J. Neurosci. Res. 87, 3671-3678. (doi:10.1002/jnr.22158)
31. Degroot, A., Köfalvi, A., Wade, M. R., Davis, R. J., Rodrigues, R. J., Rebola, N., Cunha, R. A. & Nomikos, G. G. 2006 CB1 receptor antagonism increases hippocampal acetylcholine release: site and mechanism of action. Mol. Pharmacol. 70, 1236-1245. (doi:10.1124/mol.106.024661)
32. Cachope, R., Mackie, K., Triller, A., O'Brien, J. & Pereda, A. E. 2007 Potentiation of electrical and chemical synaptic transmission mediated by endocannabinoids. Neuron 56, 1034-1047. (doi:10.1016/j.neuron.2007.11.014)
33. Salio, C., Doly, S., Fischer, J., Franzoni, M. F. & Conrath, M. 2002 Neuronal and astrocytic localization of the cannabinoid receptor-1 in the dorsal horn of the rat spinal cord. Neurosci. Lett. 329, 13-16. (doi:10.1016/S0304-3940(02)00549-9)
34. Rodriguez, J. J., Mackie, K. & Pickel, V. M. 2001 Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat caudate putamen nucleus. J. Neurosci. 21, 823-833.
35. Navarrete, M. & Araque, A. 2008 Endocannabinoids mediate neuron-astrocyte communication. Neuron 57, 883-893. (doi:10.1016/j.neuron.2008.01.029)
36. Navarrete, M. & Araque, A. 2010 Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes. Neuron 68, 113-126. (doi:10.1016/j.neuron.2010.08.043)
37. Min, R. & Nevian, T. 2012 Astrocyte signaling controls spike timing-dependent depression at neocortical synapses. Nat. Neurosci. 15, 746-753. (doi:10.1038/nn.3075)
38. Han, J. et al. 2012 Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell 148, 1039-1050. (doi:10.1016/j.cell.2012.01.037)
39. Hohmann, A. G., Briley, E. M. & Herkenham, M. 1999 Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res. 822, 17-25. (doi:10.1016/S0006-8993(9801321-3)
40. Ong, W. & Mackie, K. 1999 A light and electron microscopic study of the CB1 cannabinoid receptor in primate brain. Neuroscience 92, 1177-1191. (doi:10.1016/S0306-4522(99)00025-1)
41. Nyíri, G., Szabadits, E., Cserép, C., Mackie, K., Shigemoto, R. & Freund, T. F. 2005 GABAB and CB1 cannabinoid receptor expression identifies two types of septal cholinergic neurons. Eur. J. Neurosci. 21, 3034-3042. (doi:10.1111/j.1460-9568.2005.04146.x)
42. Bacci, A., Huguenard, J. R. & Prince, D. A. 2004 Longlasting self-inhibition of neocortical interneurons mediated by endocannabinoids. Nature 431, 312-316. (doi:10.1038/nature02913)
43. Marinelli, S., Pacioni, S., Cannich, A., Marsicano, G. & Bacci, A. 2009 Self-modulation of neocortical pyramidal neurons by endocannabinoids. Nat. Neurosci. 12, 1488-1490. (doi:10.1038/nn.2430)
44. Marinelli, S., Pacioni, S., Bisogno, T., di Marzo, V., Prince, D. A., Huguenard, J. R. & Bacci, A. 2008 The endocannabinoid 2-arachidonoylglycerol is responsible for the slow self-inhibition in neocortical interneurons. J. Neurosci. 28, 13532-13541. (doi:10.1523/JNEUROSCI.0847-08.2008)
45. Lauckner, J. E., Hille, B. & Mackie, K. 2005 The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc. Natl Acad. Sci. USA 102, 19144-19149. (doi:10.1073/pnas.0509588102)
46. Glass, M. & Felder, C. C. 1997 Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J. Neurosci. 17, 5327-5333.
47. Rios, C., Gomes, I. & Devi, L. A. 2006 Mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br. J. Pharmacol. 148, 387-395. (doi:10.1038/sj.bjp.0706757)
48. Rozenfeld, R. et al. 2012 Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons. PLoS ONE 7, e29239. (doi:10.1371/journal.pone.0029239)
49. Dalton, G. D., Bass, C. E., Van Horn, C. G. & Howlett, A. C. 2009 Signal transduction via cannabinoid receptors. CNS Neurol. Disord. Drug Targets 8, 422-431. (doi:10.2174/187152709789824615)
50. Howlett, A. C., Blume, L. C. & Dalton, G. D. 2010 CB(1) cannabinoid receptors and their associated proteins. Curr. Med. Chem. 17, 1382-1393. (doi:10.2174/092986710790980023)
51. Turu, G. & Hunyady, L. 2010 Signal transduction of the CB1 cannabinoid receptor. J. Mol. Endocrinol. 44, 75-85. (doi:10.1677/JME-08-0190)
52. Mezey, E., Tóth, Z. E., Cortright, D. N., Arzubi, M. K., Krause, J. E., Elde, R., Guo, A., Blumberg, P. M. & Szallasi, A. 2000 Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc. Natl Acad. Sci. USA 97, 3655-3660. (doi:10.1073/pnas.060496197)
53. Tóth, A., Boczán, J., Kedei, N., Lizanecz, E., Bagi, Z., Papp, Z., Edes, I., Csiba, L. & Blumberg, P. M. 2005 Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. Brain Res. Mol. Brain Res. 135, 162-168. (doi:10.1016/j.molbrainres.2004.12.003)
54. Cristino, L., de Petrocellis, L., Pryce, G., Baker, D., Guglielmotti, V. & Di Marzo, V. 2006 Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139, 1405-1415. (doi:10.1016/j.neuroscience.2006.02.074)
55. Di Marzo, V. & De Petrocellis, L. 2010 Endocannabinoids as regulators of transient receptor potential (TRP) channels: a further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr. Med. Chem. 17, 1430-1449. (doi:10.2174/092986710790980078)
56. Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H., Sørgård, M., Di Marzo, V., Julius, D. & Högestätt, E. D. 1999 Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452-457. (doi:10.1038/22761)
57. Maccarrone, M. et al. 2008 Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat. Neurosci. 11, 152-159. (doi:10.1038/nn2042)
58. Marinelli, S. et al. 2007 N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology 32, 298-308. (doi:10.1038/sj.npp.1301118)
59. Marinelli, S., di Marzo, V., Berretta, N., Matias, I., Maccarrone, M., Bernardi, G. & Mercuri, N. B. 2003 Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J. Neurosci. 23, 3136-3144.
60. Marinelli, S., Pascucci, T., Bernardi, G., Puglisi-Allegra, S. & Mercuri, N. B. 2005 Activation of TRPV1 in the VTA excites dopaminergic neurons and increases chemical- and noxious-induced dopamine release in the nucleus accumbens. Neuropsychopharmacology 30, 864-870. (doi:10.1038/sj.npp.1300615)
61. Yuan, S. & Burrell, B. D. 2010 Endocannabinoiddependent LTD in a nociceptive synapse requires activation of a presynaptic TRPV-like receptor. J. Neurophysiol. 104, 2766-2777. (doi:10.1152/jn.00491.2010)
62. Puente, N., Cui, Y., Lassalle, O., Lafourcade, M., Georges, F., Venance, L., Grandes, P. & Manzoni, O. J. 2011 Polymodal activation of the endocannabinoid system in the extended amygdala. Nat. Neurosci. 14, 1542-1547. (doi:10.1038/nn.2974)
63. Chávez, A. E., Chiu, C. Q. & Castillo, P. E. 2010 TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrus. Nat. Neurosci. 13, 1511-1518. (doi:10.1038/nn.2684)
64. Grueter, B. A., Brasnjo, G. & Malenka, R. C. 2010 Postsynaptic TRPV1 triggers cell type-specific longterm depression in the nucleus accumbens. Nat. Neurosci. 13, 1519-1525. (doi:10.1038/nn.2685)
65. Hampson, R. E., Zhuang, S., Weiner, J. L. & Deadwyler, S. A. 2003 Functional significance of cannabinoidmediated, depolarization-induced suppression of inhibition (DSI) in the hippocampus. J. Neurophysiol. 90, 55-64. (doi:10.1152/jn.01161.2002)
66. Stella, N., Schweitzer, P. & Piomelli, D. 1997 A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773-778. (doi:10.1038/42015)
67. Alger, B. E. & Kim, J. 2011 Supply and demand for endocannabinoids. Trends Neurosci. 34, 304-315. (doi:10.1016/j.tins.2011.03.003)
68. Di Marzo, V. 2009 The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol. Res. 60, 77-84. (doi:10.1016/j.phrs.2009.02.010)
69. Gao, Y. et al. 2010 Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J. Neurosci. 30, 2017-2024. (doi:10.1523/JNEUROSCI.5693-09.2010)
70. Yoshino, H. et al. 2011 Postsynaptic diacylglycerol lipase mediates retrograde endocannabinoid suppression of inhibition in mouse prefrontal cortex. J. Physiol. 589, 4857-4884. (doi:10.1113/jphysiol.2011.212225)
71. Tanimura, A. et al. 2010 The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron 65, 320-327. (doi:10.1016/j.neuron.2010.01.021)
72. Kim, J. & Alger, B. E. 2004 Inhibition of cyclooxygenase- 2 potentiates retrograde endocannabinoid effects in hippocampus. Nat. Neurosci. 7, 697-698. (doi:10.1038/nn1262)
73. Galante, M. & Diana, M. A. 2004 Group I metabotropic glutamate receptors inhibit GABA release at interneuron-Purkinje cell synapses through endocannabinoid production. J. Neurosci. 24, 4865-4874. (doi:10.1523/JNEUROSCI.0403-04.2004)
74. Melis, M. & Pistis, M. 2012 Hub and switches: endocannabinoid signalling in midbrain dopamine neurons. Phil. Trans. R. Soc. B 367, 3276-3285. (doi:10.1098/rstb.2011.0383)
75. Melis, M., Pistis, M., Perra, S., Muntoni, A. L., Pillolla, G. & Gessa, G. L. 2004 Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J. Neurosci. 24, 53-62. (doi:10.1523/JNEUROSCI.4503-03.2004)
76. Melis, M., Perra, S., Muntoni, A. L., Pillolla, G., Lutz, B., Marsicano, G., Di Marzo, V., Gessa, G. L. & Pistis, M. 2004 Prefrontal cortex stimulation induces 2-arachidonoyl- glycerol-mediated suppression of excitation in dopamine neurons. J. Neurosci. 24, 10707-10715. (doi:10.1523/JNEUROSCI.3502-04.2004)
77. Gerdeman, G. L., Ronesi, J. & Lovinger, D. M. 2002 Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat. Neurosci. 5, 446.
78. Heifets, B. D. & Castillo, P. E. 2009 Endocannabinoid signaling and long-term synaptic plasticity. Annu. Rev. Physiol. 71, 283-306. (doi:10.1146/annurev.physiol.010908.163149)
79. Chevaleyre, V. & Castillo, P. E. 2003 Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. Neuron 38, 461-472. (doi:10.1016/S0896-6273(03)00235-6)
80. Chevaleyre, V. & Castillo, P. E. 2004 Endocannabinoidmediated metaplasticity in the hippocampus. Neuron 43, 871-881. (doi:10.1016/j.neuron.2004.08.036)
81. Chevaleyre, V., Heifets, B. D., Kaeser, P. S., Südhof, T. C., Purpura, D. P. & Castillo, P. E. 2007 Endocannabinoid- mediated long-term plasticity requires cAMP/ PKA signaling and RIM1alpha. Neuron 54, 801-812. (doi:10.1016/j.neuron.2007.05.020)
82. Penzo, M. A. & Peña, J. L. 2009 Endocannabinoidmediated long-term depression in the avian midbrain expressed presynaptically and postsynaptically. J. Neurosci. 29, 4131-4139. (doi:10.1523/JNEUROSCI.5466-08.2009)
83. Sjöström, P. J., Turrigiano, G. G. & Nelson, S. B. 2003 Neocortical LTD via coincident activation of presynaptic NMDA and cannabinoid receptors. Neuron 39, 641-654. (doi:10.1016/S0896-6273(03)00476-8)
84. Bender, V. A., Bender, K. J., Brasier, D. J. & Feldman, D. E. 2006 Two coincidence detectors for spike timingdependent plasticity in somatosensory cortex. J. Neurosci. 26, 4166-4177. (doi:10.1523/JNEUROSCI.0176-06.2006)
85. Edwards, J. G., Gibson, H. E., Jensen, T., Nugent, F., Walther, C., Blickenstaff, J. & Kauer, J. A. 2012 A novel non-CB1/TRPV1 endocannabinoid-mediated mechanism depresses excitatory synapses on hippocampal CA1 interneurons. Hippocampus 22, 209-221. (doi:10.1002/hipo.20884)
86. Bennett, M. V. L. & Zukin, R. S. 2004 Electrical coupling and neuronal synchronization in the mammalian brain. Neuron 41, 495-511. (doi:10.1016/S0896-6273(04)00043-1)
87. Condorelli, D. 2000 Expression of Cx36 in mammalian neurons. Brain Res. Rev. 32, 72-85. (doi:10.1016/S0165-0173(99)00068-5)
88. Connors, B.W. & Long, M. A. 2004 Electrical synapses in the mammalian brain. Annu. Rev. Neurosci. 27, 393-418. (doi:10.1146/annurev.neuro.26.041002.131128)
89. Pereda, A. E. & Faber, D. S. 1996 Activity-dependent short-term enhancement of intercellular coupling. J. Neurosci. 16, 983-992.
90. Smith, M. & Pereda, A. E. 2003 Chemical synaptic activity modulates nearby electrical synapses. Proc. Natl Acad. Sci. USA 100, 4849-4854. (doi:10.1073/pnas.0734299100)
91. Venance, L., Piomelli, D., Glowinski, J. & Giaume, C. 1995 Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature 376, 590-594. (doi:10.1038/376590a0)
92. Smart, D., Gunthorpe, M. J., Jerman, J. C., Nasir, S., Gray, J., Muir, A. I., Chambers, J. K., Randall, A. D. & Davis, J. B. 2000 The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (HVR1). Br. J. Pharmacol. 129, 227-230. (doi:10.1038/sj.bjp.0703050)
93. Huang, S. M. et al. 2002 An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl Acad. Sci. USA 99, 8400-8405. (doi:10.1073/pnas.122196999)
94. Zias, J., Stark, H., Sellgman, J., Levy, R., Werker, E., Breuer, A. & Mechoulam, R. 1993 Early medical use of cannabis. Nature 363, 215. (doi:10.1038/363215a0)
95. Bossong, M. G. & Niesink, R. J. M. 2010 Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Prog. Neurobiol. 92, 370-385. (doi:10.1016/j.pneurobio.2010.06.010)
96. Kolliakou, A., Joseph, C., Ismail, K., Atakan, Z. & Murray, R. M. 2011 Why do patients with psychosis use cannabis and are they ready to change their use? Int. J. Dev. Neurosci. 29, 335-346. (doi:10.1016/j.ijdevneu.2010.11.006)
97. D'Souza, D. C., Sewell, R. A. & Ranganathan, M. 2009 Cannabis and psychosis/schizophrenia: human studies. Eur. Arch. Psychiatry Clin. Neurosci. 259, 413-431. (doi:10.1007/s00406-009-0024-2)
98. Zavitsanou, K., Garrick, T. & Huang, X. F. 2004 Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 28, 355-360. (doi:10.1016/j.pnpbp.2003.11.005)
99. Newell, K. A., Deng, C. & Huang, X.-F. 2006 Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp. Brain Res. 172, 556-560. (doi:10.1007/s00221-006-0503-x)
100. Dean, B., Sundram, S., Bradbury, R., Scarr, E. & Copolov, D. 2001 Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103, 9-15. (doi:10.1016/S0306-4522(00)00552-2)
101. Eggan, S. M., Hashimoto, T. & Lewis, D. A. 2008 Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch. Gen. Psychiatry 65, 772-784. (doi:10.1001/archpsyc.65.7.772)
102. De Marchi, N., De Petrocellis, L., Orlando, P., Daniele, F., Fezza, F. & Di Marzo, V. 2003 Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 2, 5. (doi:10.1186/1476-511X-2-5)
103. Giuffrida, A., Leweke, F. M., Gerth, C. W., Schreiber, D., Koethe, D., Faulhaber, J., Klosterkötter, J. & Piomelli, D. 2004 Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29, 2108-2114. (doi:10.1038/sj.npp.1300558)
104. Leweke, F. M. et al. 2007 Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr. Res. 94, 29-36. (doi:10.1016/j.schres.2007.04.025)
105. Seillier, A., Advani, T., Cassano, T., Hensler, J. G. & Giuffrida, A. 2010 Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. Int. J. Neuropsychopharmacol. 13, 373-386. (doi:10.1017/S146114570999023X)
106. Kumar, P., Kalonia, H. & Kumar, A. 2010 Huntington's disease: pathogenesis to animal models. Pharmacol. Rep. 62, 1-14. (doi:10.1016/j.physrep.2009.11.001)
107. Glass, M., Dragunow, M. & Faull, R. L. 2000 The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97, 505-519. (doi:10.1016/S0306-4522(00)00008-7)
108. Dowie, M. J., Bradshaw, H. B., Howard, M. L., Nicholson, L. F. B., Faull, R. L. M., Hannan, A. J. & Glass, M. 2009 Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. Neuroscience 163, 456-465. (doi:10.1016/j.neuroscience.2009.06.014)
109. Allen, K. L., Waldvogel, H. J., Glass, M. & Faull, R. L. M. 2009 Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease. J. Chem. Neuroanat. 37, 266-281. (doi:10.1016/j.jchemneu.2009.02.001)
110. McCaw, E. A., Hu, H., Gomez, G. T., Hebb, A. L. O., Kelly, M. E. M. & Denovan-Wright, E. M. 2004 Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur. J. Biochem. 271, 4909-4920. (doi:10.1111/j.1432-1033.2004.04460.x)
111. Bisogno, T., Martire, A., Petrosino, S., Popoli, P. & di Marzo, V. 2008 Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease. Neurochem. Int. 52, 307-313. (doi:10.1016/j.neuint.2007.06.031)